The catalyst-assisted synthesis of high quality CdS single-crystal nanowires through an epitaxy mechanism.

J Nanosci Nanotechnol

State Key Laboratory for Physical Chemistry of Solid Surface, Department of Chemistry, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, PR China.

Published: September 2007

High quality wurtzite CdS nanowires have been synthesized by thermal evaporation of CdS powder onto Si substrate in the presence of Au catalyst at 650 degrees C by using pure H2 as a carrier gas. The nanowires were 10 nm in diameter and a few tens of micrometers in length. XRD patterns demonstrated that as prepared CdS is a pure crystalline material. High-resolution transmission electron microscopy of the materials showed that all CdS nanowires grew along (0001). According to analysis of selective area electron diffraction patterns taken from the interface, we proposed that there is a kind of epitaxy relationship in the interface region between Au catalyst and CdS grown, i.e., (0001)CdS // (111)Au, and [1210]CdS // [011]Au.

Download full-text PDF

Source
http://dx.doi.org/10.1166/jnn.2007.697DOI Listing

Publication Analysis

Top Keywords

high quality
8
cds nanowires
8
cds
6
catalyst-assisted synthesis
4
synthesis high
4
quality cds
4
cds single-crystal
4
nanowires
4
single-crystal nanowires
4
nanowires epitaxy
4

Similar Publications

Background: This study investigates a multi-angle acquisition method aimed at improving image quality in organ-targeted PET detectors with planar detector heads. Organ-targeted PET technologies have emerged to address limitations of conventional whole-body PET/CT systems, such as restricted axial field-of-view (AFOV), limited spatial resolution, and high radiation exposure associated with PET procedures. The AFOV in organ-targeted PET can be adjusted to the organ of interest, minimizing unwanted signals from other parts of the body, thus improving signal collection efficiency and reducing the dose of administered radiotracer.

View Article and Find Full Text PDF

Mass spectrometry (MS)-based metabolomics often rely on separation techniques when analyzing complex biological specimens to improve method resolution, metabolome coverage, quantitative performance, and/or unknown identification. However, low sample throughput and complicated data preprocessing procedures remain major barriers to affordable metabolomic studies that are scalable to large populations. Herein, we introduce PeakMeister as a new software tool in the R statistical environment to enable standardized processing of serum metabolomic data acquired by multisegment injection-capillary electrophoresis-mass spectrometry (MSI-CE-MS), a high-throughput separation platform (<4 min/sample) which takes advantage of a serial injection format of 13 samples within a single analytical run.

View Article and Find Full Text PDF

In recent years, China has significantly increased its global competitiveness in digital technologies, emphasizing the importance of the digital economy during the high-quality development stage. The question of how firms in traditional industries can achieve digital transformation, which is critical for participating in the digital economy, is still understudied. Using the ability-motivation-opportunity (AMO) framework, this research developed a model and identified six factors' ability, motivation, and opportunity dimensions.

View Article and Find Full Text PDF

Background: Breast cancer is a significant global health issue, responsible for a large number of female cancer deaths. Early detection through breast cancer screening is crucial in reducing mortality rates. However, regions such as Sub-Saharan Africa (SSA) face challenges in identifying breast cancer early, resulting in higher mortality rates and a lower quality of life.

View Article and Find Full Text PDF

Mirvetuximab Soravtansine in solid tumors: A systematic review and meta-analysis.

PLoS One

December 2024

Department of Obstetrics and Gynaecology, West China Second University Hospital, Sichuan University, Chengdu, China.

Background: Mirvetuximab Soravtansine (MIRV) is a promising antibody‒drug conjugate (ADC) that targets folate receptor alpha (FRα), which is overexpressed in several types of solid tumors. In November 2022, MIRV was approved in the USA for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who received 1-3 prior systemic treatment regimens. Therefore, high-quality evidence for its efficacy and safety in different cancers is urgently needed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!